文献速递银屑病与炎症性皮肤病

阿普米司特治疗银屑病的真实世界前瞻性研究

Apremilast in psoriasis - a prospective real-world study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-10-12

中位药物生存期为12.5周,仅6.3%达PASI90;体重与PASI50反应负相关,肥胖患者无PASI75;64.6%报告不良事件,最常见腹泻。

要点

  • 阿普米司特真实世界中位药物生存期仅12.5周。
  • 不足20%患者达PASI75,仅6.3%达PASI90。
  • 体重与PASI50反应负相关,肥胖患者无PASI75。

核心结论

  • 阿普米司特在日常实践治疗皮肤银屑病安全有效。
  • 高达40%患者可达PASI50或更高,但仅少数达PASI90。
  • 体重可能影响药物疗效。

研究设计与样本

  • 前瞻性真实世界研究,纳入2015年4月1日至2017年1月19日接受阿普米司特的银屑病患者。
  • 采用Kaplan-Meier统计估计药物生存率。

主要发现

  • 中位阿普米司特药物生存期为12.5周(范围1-87)。
  • 3例(6.3%)达PASI90,9例(18.8%)达PASI75,8例(16.7%)达PASI50。
  • 患者体重与PASI50反应呈负相关(P < 0.05,n = 37)。
  • 肥胖患者(BMI > 30.0,n = 6)无一达PASI75,而非肥胖患者(BMI < 30.0,n = 31)中32%达PASI75。
  • 31例(64.6%)报告至少一种不良事件,最常见为腹泻(n = 21,43.8%)、头痛(n = 7,14.6%)和关节痛(n = 5,10.4%)。

关键数值与推荐

  • 疗效以PASI50、PASI75、PASI90评估,反映皮损较基线改善程度。
  • 药物生存率采用Kaplan-Meier统计估计。

临床怎么用

  • 阿普米司特可用于日常实践治疗皮肤银屑病,但需预期多数患者无法达到PASI90。
  • 体重可能影响疗效,肥胖患者应答可能较差。
  • 治疗中需监测腹泻、头痛和关节痛等不良事件。

局限性

  • 真实世界患者与临床试验患者存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apremilast is a novel oral phosphodiesterase-4 inhibitor approved for psoriasis treatment. Randomized trials have documented its efficacy and safety, but data on real-world patients are scarce. OBJECTIVES: We aim to characterize psoriasis patients treated with apremilast in a real-world setting and calculate drug survival as an important measure of efficacy and compliance. METHODS: All patients with psoriasis who received apremilast between 1 April 2015 and 19 January 2017 were evaluated every 4 weeks, and we documented: age, weight, height, smoking status, family history of psoriasis, joint involvement, previous treatments, psoriasis area severity index (PASI) scores, and the onset and duration of adverse events (AE). Efficacy was analysed by PASI50, PASI75 and PASI90, reflecting the improvement of skin lesions compared to the PASI-baseline. Kaplan-Meier statistics were used for drug survival estimates. RESULTS: Forty-eight patients were included. The median apremilast drug survival was 12.5 weeks (range 1-87). Three patients (6.3%) reached PASI90, nine (18.8%) PASI75 and eight patients (16.7%) PASI50. Patient weight inversely correlated with a PASI50 response (P < 0.05, n = 37), and none of the obese patients (BMI > 30.0, n = 6) reached PASI75, compared to 32% of the non-obese patients (BMI < 30.0, n = 31). Thirty-one patients (64.6%) reported at least one AE, most frequently diarrhoea (n = 21, 43.8%), headache (n = 7, 14.6%) and joint pain (n = 5, 10.4%). CONCLUSIONS: Despite differences between real-world and trial patients, apremilast is safe and effective for the treatment of skin psoriasis in the daily practice. Up to 40% of patients will reach PASI50 or higher, but only few patients will reach PASI90. Bodyweight might affect drug efficacy.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Vujic I, Herman R, Sanlorenzo M, et al. Apremilast in psoriasis - a prospective real-world study. J Eur Acad Dermatol Venereol. 2017. PMID: 28925560. doi:10.1111/jdv.14598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。